RAI14 and prostate cancer: In past decades, several research studies have shown that RAI14 was higher in a wide range of malignancies, containing esophageal cancer (Wang et al., 2020b), gastric cancer (Chen et al., 2018; He et al., 2018; Meng et al., 2020; Xiao et al., 2020), lung adenocarcinoma (Yuan et al., 2017), ovarian cancer (Hawkins et al., 2013), and prostate cancer (Paez et al., 2016), and positively related to the progression of neoplasms.